Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen

Porporatto, 2005, Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration, J Leukoc Biol, 78, 62, 10.1189/jlb.0904541 Babensee, 2005, Differential levels of dendritic cell maturation on different biomaterials used in combination products, J Biomed Mater Res A, 74, 503, 10.1002/jbm.a.30429 Chopra, 2006, Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery, J Pharm Pharmacol, 58, 1021, 10.1211/jpp.58.8.0002 Thanou, 2001, Chitosan and its derivatives as intestinal absorption enhancers, Adv Drug Deliv Rev, 50, S91, 10.1016/S0169-409X(01)00180-6 van der Lubben, 2001, Chitosan for mucosal vaccination, Adv Drug Deliv Rev, 52, 139, 10.1016/S0169-409X(01)00197-1 O'Hagan, 2006, Microparticles as vaccine delivery systems, 123 Craven, 1986, Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings, Ann Intern Med, 105, 356, 10.7326/0003-4819-105-3-356 Mast, 2006, A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults, MMWR Recomm Rep, 55, 1 Rahman, 2000, Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen, Hepatology, 31, 521, 10.1002/hep.510310237 Weeratna, 2001, CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice, FEMS Immunol Med Microbiol, 32, 65, 10.1111/j.1574-695X.2001.tb00535.x Steinke, 2006, 3. Cytokines and chemokines, J Allergy Clin Immunol, 117, S441, 10.1016/j.jaci.2005.07.001 Constant, 1997, Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches, Annu Rev Immunol, 15, 297, 10.1146/annurev.immunol.15.1.297 Rehermann, 2005, Immunology of hepatitis B virus and hepatitis C virus infection, Nat Rev Immunol, 5, 215, 10.1038/nri1573 Moldoveanu, 1998, CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus, Vaccine, 16, 1216, 10.1016/S0264-410X(98)80122-9 McCluskie, 2002, Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA, FEMS Immunol Med Microbiol, 32, 179, 10.1111/j.1574-695X.2002.tb00551.x Osorio, 2003, Immune responses to hepatitis B surface antigen following epidermal powder immunization, Immunol Cell Biol, 81, 52, 10.1046/j.1440-1711.2003.01134.x Davis, 1998, CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen, J Immunol, 160, 870, 10.4049/jimmunol.160.2.870 Diwan, 2002, Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres, J Control Release, 85, 247, 10.1016/S0168-3659(02)00275-4 Borges, 2005, Preparation of coated nanoparticles for a new mucosal vaccine delivery system, Int J Pharm, 299, 155, 10.1016/j.ijpharm.2005.04.037 Borges, 2006, Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination., J Control Release, 114, 348, 10.1016/j.jconrel.2006.06.011 Borges, 2007, Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles, Eur J Pharm Sci, 32, 278, 10.1016/j.ejps.2007.08.005 Cordeiro-da-Silva, 2004, Immunological alterations induced by polyamine derivatives on murine splenocytes and human mononuclear cells, Int Immunopharmacol, 4, 547, 10.1016/j.intimp.2004.02.009 Weeratna, 2000, CpG DNA induces stronger immune responses with less toxicity than other adjuvants, Vaccine, 18, 1755, 10.1016/S0264-410X(99)00526-5 Joseph, 2008, Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles, Eur J Pharm Biopharm, 69, 405, 10.1016/j.ejpb.2008.01.019 Borges, 2008, Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles, Eur J Pharm Biopharm, 69, 405, 10.1016/j.ejpb.2008.01.019 McNeela, 2000, A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery, Vaccine, 19, 1188, 10.1016/S0264-410X(00)00309-1 Jung, 2002, Immunology of hepatitis B infection, Lancet Infect Dis, 2, 43, 10.1016/S1473-3099(01)00172-4 Goyal, 2006, Nanodecoy system: a novel approach to design hepatitis B vaccine for immunopotentiation, Int J Pharm, 309, 227, 10.1016/j.ijpharm.2005.11.037 He, 2005, Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles, J Control Release, 107, 357, 10.1016/j.jconrel.2005.06.020 Chong, 2005, Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery, J Control Release, 102, 85, 10.1016/j.jconrel.2004.09.014 Manning, 2001, CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice, Exp Gerontol, 37, 107, 10.1016/S0531-5565(01)00157-7 Bachmann, 1993, The influence of antigen organization on B cell responsiveness, Science, 262, 1448, 10.1126/science.8248784 Gursel, 2001, Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides, J Immunol, 167, 3324, 10.4049/jimmunol.167.6.3324 Gursel, 1999, Immunoadjuvant action of plasmid DNA in liposomes, Vaccine, 17, 1376, 10.1016/S0264-410X(98)00383-1 Li, 2001, Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes, Vaccine, 20, 148, 10.1016/S0264-410X(01)00277-8 Klinman, 2004, Use of CpG oligodeoxynucleotides as immune adjuvants, Immunol Rev, 199, 201, 10.1111/j.0105-2896.2004.00148.x Singh, 2001, Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA, Pharm Res, 18, 1476, 10.1023/A:1012269226066 Danielsen, 2004, Structural analysis of chitosan mediated DNA condensation by AFM: influence of chitosan molecular parameters, Biomacromolecules, 5, 928, 10.1021/bm034502r Dang, 2006, Natural polymers for gene delivery and tissue engineering, Adv Drug Deliv Rev, 58, 487, 10.1016/j.addr.2006.03.001 Krieg, 2006, Therapeutic potential of Toll-like receptor 9 activation, Nat Rev Drug Discov, 5, 471, 10.1038/nrd2059 Wu, 2006, A novel chitosan CpG nanoparticle regulates cellular and humoral immunity of mice, Biomed Environ Sci, 19, 87 Fu, 2006, Regulating effects of novel CpG chitosan-nanoparticles on immune responses of mice to porcine paratyphoid vaccines, Biomed Environ Sci, 19, 315 Richardson, 1999, Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA, Int J Pharm, 178, 231, 10.1016/S0378-5173(98)00378-0 Davis, 2006, The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery, Vaccine, 24 Prego, 2005, The potential of chitosan for the oral administration of peptides, Expert Opin Drug Deliv, 2, 843, 10.1517/17425247.2.5.843 Prabaharan, 2005, Chitosan-based particles as controlled drug delivery systems, Drug Deliv, 12, 41, 10.1080/10717540590889781 Kurita, 2006, Chitin and chitosan: functional biopolymers from marine crustaceans, Mar Biotechnol (NY), 8, 203, 10.1007/s10126-005-0097-5 van der Lubben, 2003, Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice, Vaccine, 21, 1400, 10.1016/S0264-410X(02)00686-2 Baudner, 2005, Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform, J Drug Target, 13, 489, 10.1080/10611860500353195 Bivas-Benita, 2004, Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A⁎0201-restricted T-cell epitopes of Mycobacterium tuberculosis, Vaccine, 22, 1609, 10.1016/j.vaccine.2003.09.044 Kang, 2006, In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT, Eur J Pharm Biopharm, 63, 215, 10.1016/j.ejpb.2006.01.010 Zaharoff, 2007, Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination, Vaccine, 25, 2085, 10.1016/j.vaccine.2006.11.034